SPSusmita Parashar

Susmita Parashar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Susmita Parashar has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Viola Vaccarino

    Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA

    7 shared publications
  • Kimberly J. Reid

    Division of Cardiology, Mid America Heart Institute, Kansas City, MO

    4 shared publications
  • John A. Spertus

    Division of Cardiology, Mid America Heart Institute, Kansas City, MO

    3 shared publications
  • Fengming Tang

    Division of Cardiology, Mid America Heart Institute, Kansas City, MO

    2 shared publications
  • Nazeera Dawood

    From the Department of Medicine (S.P., N.D., S.K., V.V.), Emory University School of Medicine, Atlanta, Ga; Denver VA Medical Center (J.S.R.), Denver, Colo; Mid America Heart Institute (K.J.R., D.B.), Kansas City, Mo; and the Department of Epidemiology and Public Health (J.L.), Yale University School of Medicine, New Haven, Conn

    2 shared publications
  • Alice M. Arnold

    Department of Epidemiology, University of Washington, Seattle Epidemiologic Research and Information Center, Seattle

    1 shared publication

Latest Publications

  • Open Access

    Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy

    by Olivia Y Hung, Jennifer R Brown, Tian Dai, Kirk A Easley, Christopher R Flowers, Susmita Parashar

    Objective Anthracyclines are potent antineoplastic agents in the treatment of lymphoid malignancies, but their therapeutic benefit is limited by cardiotoxicity. The American Heart Association (AHA) recommends routine surveillance, early diagnosis and treatment of anthracycline-based chemotherapy (AC) induced cardiomyopathy (AC-CMP). We aimed to assess the prevalence of AC-CMP in patients with lymphoma, surveillance patterns of left ventricular ejection fraction (LVEF) in those receiving AC and management of patients with AC-CMP at an academic medical centre prior to the development of a comprehensive cardio-oncology programme. Methods We performed a retrospective cohort study examining 218 patients with aggressive B cell non-Hodgkin's lymphomas (B-NHL) who received AC 1992–2012 and had serial follow-up. AC-CMP was defined as LVEF decrease ≥10% with final LVEF≤50% or LVEF reduction ≥15% regardless of final LVEF. Results Of 218 patients treated with AC, 73 (34%) had LVEF assessment both prior to and after receiving AC. Of these 73 patients, 24 developed AC-CMP and had higher cumulative all-cause mortality than those without AC-CMP (HR 2.35, p=0.03). Coronary artery disease (CAD) was an independent predictor of AC-CMP (p=0.048). Mean post-AC LVEF was lower in patients with CAD compared with those without CAD when their baseline LVEF was 45% (p=0.0009) or 55% (p=0.001) but was similar at 65% (p=0.33). Less than half of patients with AC-CMP received recommended heart failure medication therapy. Conclusions Historically, one-third of patients with B-NHL treated with AC underwent surveillance according to AHA guidelines. There is substantial opportunity for collaboration between oncologists and cardiologists to improve the care of patients with lymphoma receiving AC.


  • New-Onset Atrial Fibrillation After Acute Myocardial Infarction and Its Relation to Admission Biomarkers (from the TRIUMPH Registry)

    by Susmita Parashar, Danesh Kella, Kimberly J. Reid, John A. Spertus, Fengming Tang, Jonathan Langberg, Viola Vaccarino, Michael C. Kontos, Renato D. Lopes, Michael S. Lloyd


  • Predictors of Early and Late Enrollment in Cardiac Rehabilitation, Among Those Referred, After Acute Myocardial Infarction

    by Susmita Parashar, John A. Spertus, Fengming Tang, Kathy L. Bishop, Viola Vaccarino, Charles F. Jackson, Thomas F. Boyden, Laurence Sperling

    Background—Cardiac rehabilitation (CR) after acute myocardial infarction (AMI) is a Class I recommendation. Although referral to CR after an AMI has recently become a performance measure, many patients may not participate. To illuminate potential barriers to participation, we examined the prevalence of, and patient-related factors associated with, CR participation within 1 and 6 months after an AMI. Methods and Results—We studied 2096 AMI patients enrolled from 19 US sites in the Prospective Registry Evaluating outcomes after Myocardial Infarction: Events and Recovery (PREMIER) registry. Analyses were limited to those patients referred for CR at the time of AMI hospitalization. A multivariable, conditional logistic regression model, stratified by hospital, was used to identify sociodemographic, comorbidity, and clinical factors independently associated with CR participation within 1 and 6 months of AMI hospital discharge. Only 29% (419/1450) and 48.25% (650/1347) of AMI patients who received referral for CR participated within 1 and 6 months after discharge, respectively. Women (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.44–0.86), uninsured (OR, 0.39; 95% CI, 0.21–0.71), and patients with hypertension (OR, 0.58; 95% CI, 0.43–0.78) and peripheral arterial disease (OR, 0.43; 95% CI, 0.22–0.85) were less likely to participate at 1 month. At 6 months after AMI, older patients (OR, 0.85 for each 10-year increment; 95% CI, 0.74–0.97), smokers (OR, 0.59; 95% CI, 0.44–0.80), and patients with economic burden (OR, 0.56; 95% CI, 0.38–0.81) were less likely to participate. Caucasians (OR, 1.73; 95% CI, 1.16–2.58) and educated patients (OR, 1.81; 95% CI, 1.42–2.30) were more likely to participate at 6 months. Patients with previous percutaneous interventions were less likely to participate at both 1 and 6 months post-AMI. Conclusions—Among patients referred for CR post-AMI, participation remains low both at 1 and 6 months after AMI. Because CR is associated with beneficial changes in cardiovascular risk factors and better outcomes after AMI, more aggressive efforts are needed to increase CR participation after referral.


  • Early menopause predicts angina after myocardial infarction

    by Susmita Parashar, Kimberly J. Reid, John A. Md Spertus, Leslee J. Shaw, Viola Vaccarino

    Objective: Population studies have shown that age at menopause (AAM) predicts coronary heart disease. It is unknown, however, whether early menopause predicts post-myocardial infarction (MI) angina. We examined whether younger AAM increases risk of post-MI angina. Methods: In a prospective multicenter MI registry, 493 postmenopausal women were enrolled (mean ± SD age, 65.4 ± 11.3 y, and mean ± SD AAM, 45.2 ± 7.8 y). We categorized AAM into 40 years or younger, 41 to 49 years, and 50 years or older. In the multivariable analysis, we examined whether AAM predicted 1-year post-MI angina and severity of angina after adjusting for angina before MI, demographics, comorbidities, MI severity, and quality of care (QOC). Results: Women with early AAM (≤40 y; n = 132, 26.8%) were younger and more often smokers but were as likely to have comorbidities as were women with an AAM of 50 years or older. Although there were no differences in pre-MI angina, MI severity, obstructive coronary disease, and QOC based on AAM, the rate of 1-year angina was higher in women with an AAM of 40 years or younger (32.4%) than in women with an AAM of 50 years or older (12.2%). In the multivariable analysis, women with an AAM of 40 years or younger had more than twice the risk of angina (relative risk, 2.09; 95% CI, 1.38-3.17) and a higher severity of angina (odds ratio, 2.65; 95% CI, 1.34-5.22 for a higher severity level) compared with women with an AAM of 50 years or older. Conclusions: Women with early menopause are at higher risk of angina after MI, independent of comorbidities, severity of MI, and QOC. The use of a simple question regarding AAM may help in the identification of women who need closer follow-up, careful evaluation, and intervention to improve their symptoms and quality of life after MI.


  • Race, Gender, and Mortality in Adults ≥65 Years of Age With Incident Heart Failure (from the Cardiovascular Health Study)

    by Susmita Parashar, Ronit Katz, Nicholas L. Smith, Alice M. Arnold, Viola Vaccarino, Nanette K. Wenger, John S. Gottdiener


  • Impact of Depression on Sex Differences in Outcome After Myocardial Infarction

    by Susmita Parashar, John S. Rumsfeld, Kimberly J. Reid, Donna Buchanan, Nazeera Dawood, Saadia Khizer, Judith Lichtman, Viola Vaccarino

    Background— Women have an unexplained worse outcome after myocardial infarction (MI) compared with men in many studies. Depressive symptoms predict adverse post-MI outcomes and are more prevalent among women than men. We examined whether depressive symptoms contribute to women’s worse outcomes after MI. Methods and Results— In a prospective multicenter study (PREMIER), 2411 (807 women) MI patients were enrolled. Depressive symptoms were assessed with the Patient Health Questionnaire. Outcomes included 1-year rehospitalization, presence of angina using the Seattle Angina Questionnaire, and 2-year mortality. Multivariable analyses were used to evaluate the association between sex and these outcomes, adjusting for clinical characteristics. The depressive symptoms score was added to the models to evaluate whether it attenuated the association between sex and outcomes. Depressive symptoms were more prevalent in women compared with men (29% versus 18.8%, P Conclusions— A higher prevalence of depressive symptoms in women modestly contributes to their higher rates of rehospitalization and angina compared with men but not mortality after MI. Our results support the recent recommendations of improving recognition of depressive symptoms after MI.


  • Open Access

    Predictors of Smoking Cessation After a Myocardial InfarctionThe Role of Institutional Smoking Cessation Programs in Improving Success

    by Nazeera Dawood, Viola Vaccarino, Kimberly J. Reid, John A. Spertus, Nesruddin Hamid, Susmita Parashar

    Smoking has long been recognized as an important risk factor for acute myocardial infarction (MI) and coronary heart disease (CHD).1,2 Smoking cessation is associated with a reduction in readmission rates and up to a 50% lower mortality in patients with established cardiovascular disease.3-5 In fact, smoking cessation may be more effective in reducing mortality in patients with MI than therapy with aspirin, β-blockers, or angiotensin-converting enzyme inhibitors.6 However, despite the clear benefits of smoking cessation after MI, only one-third to one-half of patients who smoke at the time of MI subsequently quit.7


  • Depression and CHD risk: How should we intervene?

    by Susmita Parashar, Viola Vaccarino

    Depression is common in the community and is a risk factor for the development of coronary heart disease (CHD). In patients with CHD, the prevalence of major depression is nearly 20% and the prevalence of minor depressive disorder is approximately 27%. When present in patients with existing CHD, depression is independently associated with worse outcome, including higher morbidity and mortality, and worse health status. Observational studies suggest that use of antidepressant medications in patients with CHD is associated with decreased risk of cardiovascular events. However, only one randomized controlled trial, the ENRICHD (Enhancing Recovery in Coronary Heart Disease) study, was designed to evaluate whether treatment of depression in patients with CHD can improve cardiac prognosis. Although the study showed that cognitive behavior therapy was better than usual care in improving depression, there was no improvement in all-cause mortality or recurrent cardiac events. There have been no clinical trials specifically designed to evaluate whether pharmacologic treatment of depression improves cardiovascular outcomes in patients with CHD. Thus, there is a clear need for additional trials testing interventions to improve cardiac prognosis based on treatment of depression. In the meantime, depression remains an important illness in its own right and deserves treatment. Safe and effective treatments of depression in patients with CHD include cognitive behavior therapy and selective serotonin reuptake inhibitors.